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Glycophorin A (GPA) assays for human erythrocytes with gene expression loss and duplication
phenotypes (N0, NN) were carried out on 15 Chernobyl clean-up workers (liquidators) who
immigrated to Israel within the preceding 5 years, 19 local Israeli controls, and 14 Russian
(nonliquidator) immigrants. GPA phenotype variants in red blood cells of the 15 liquidators
showed values ranging from 1 to 101 events/106 cells, with a mean ±SD of 25.6 ±7.0. In
comparison, the 19 Israeli controls had values ranging from 0 to 13 GPA events per 106 cells,
with a mean ±SD of 3.9 ±0.8. The difference was highly significant (p<0.001). Another group of
14 volunteer control subjects (nonliquidators) who had emigrated from the former Soviet Union to
Israel during the past 5 years showed values ranging from 0.0 to 35.0 events per 106 cells, with a
mean ±SD of 6.1 ±2.7. The difference between this group and the liquidator group was
significant at p<0.01. The results are compatible with past exposure to radiation in the group
identified as liquidators. - Environ Health Perspect 105(Suppl 6):1451-1454 (1997)
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Introduction
On 26 April 1986 there was an explosion
and fire in reactor number 4 of the
Chernobyl power plant. More than 1018
Bq of radioactive substances were released
into the atmosphere, including 1.4 x 108
Ci of 1-131 and other short-lived radio-
iodines that were dispersed by winds and
precipitated with rain. People over vast
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areas were exposed to variable amounts of
P- and y- irradiations from the emitted
radioisotopes. A subgroup ofthis popula-
tion consisted ofsalvage or clean-up work-
ers, called liquidators, sent to work during
and after the accident in different jobs near
and within the damaged reactor. Their
total number has been estimated to be as
high as 600,000. Although their exposure
was supposed to have been limited to 25
cSv, the actual radiation doses that these
people received is not clear.
During 1990, mass migration to Israel
from the former Soviet Union (FSU)
started, and by 1996 about 700,000 people
had come to Israel. Roughly 20% ofthis
number is estimated to have emigrated from
radiocontaminated areas ofBelarus, Russia,
and Ukraine. Within this immigrant group
were a limited number ofdean-up workers.
The presence ofthese people in Israel has
led to the possibility ofestimating the extent
ofpast radiation exposure using various bio-
logical indicators (1).
The somatic mutation test ofhuman ery-
throcytes with gene expression loss and
duplication phenotypes at the glycophorin A
(GPA) locus (2) has been found to be a sen-
sitive indicator ofexposure to radiation in
atom bomb survivors (3), individuals
exposed in the Goiania accident (4), and in
Chernobyl-exposed groups (5-7).
In the presentwork, our objective was to
apply the GPA somatic mutation assay to a
group ofChernobyl clean-up workers who
immigrated to Israel and to compare them
with unexposed control subjects in Israel
and immigrants who came from various
areas ofthe FSU.
Materials and Methods
Subjects
Of41 volunteer clean-up workers who had
official papers identifying themselves as
liquidators or clean-up workers at the
Chernobyl nuclear power plant, only 15
were identified as having the MN blood
type. There were two groups of control
subjects. The first group consisted of40
Israeli residents who had not come from
FSU countries, ofwhom 19 had the MN
blood type. The second group of 26 con-
trols were emigrants from FSU countries to
Israel who were selected randomly; ofthese
14 had the MN blood type.
The age range of the liquidators with
blood type MN was 30 to 63 years ofage
(73% male), Israeli MN controls were 20
to 69 years of age (47% male), and the
FSU MN controls were 27 to 64 years of
age (29% male).
Methodology
Peripheral bloodwas obtained byvenipunc-
ture from each volunteer. Each sample con-
sisted of 5 to 10 ml ofheparinized blood.
The samples were coded and each sample
was tested for determination of the blood
type-MM, MN, or NN. This was done
using commercial anti-M and anti-N anti-
bodies obtained from Ortho Diagnostic
Systems Inc. (Raritan, NJ). Identification of
the blood types was carried out according
to the commercial instructions.
The flow cytometric assay for N0 and
NN phenotypes was performed according
to the BR6 method ofLanglois et al. (8).
The assay enumerates the frequency ofN0
and NN phenotypes in a cell population of
MN blood type. This procedure can be
performed only on the 50% ofthe popula-
tion expressing the heterozygous MN phe-
notype. The assay uses immunofluorescence
labeling and flow cytometry to enumerate
the frequency of red blood cells lacking
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expression or showing duplication ofone
allele. The fluorescent anti-M antibody
(6A7) labeled with rodamine, and the fluo-
rescent anti-N labeled with fluorescein
isothiocyanate (FITC) were obtained from
the International Blood Group Reference
Laboratory (Bristol, U.K.).
The blood was fixed and labeled with
fluorescent monoclonal antibodies and
analyzed by flow cytometry using a Becton
-Dickinson FACSTAR (San Jose, CA) flu-
orescence-activated cell sorter (FACS). The
time taken from drawing the blood to
FACS analysis was 5 to 14 days, during
which time the whole blood samples were
kept at 40C.
The results are the sum of both N0
and NN phenotypes.
StatisticalAnalysis
Comparison was made between the results
obtained from the liquidators and the two
control groups using the Student's t-test
and the Mann-Whitney test.
Results
The results ofthe study are summarized in
Figure 1. The 19 Israeli controls showed
tight distribution within the range of0 to 13
per 106 cells. The mean ±SD was 3.9 ±0.8.
In contrast, the 15 liquidators showed values
ranging from 1 to 101 per 106 cells, with a
mean ±SD of25.5 ±7.0. The difference was
highlysignificant atp<0.001.
To determine whether the difference
was due to radiation exposure at Chernobyl
or to differences between the people living
in areas of the FSU and to those in Israel
who did not come from the FSU, a second
group of controls was obtained. The 14
MN control individuals in the latter group
had values ranging from 0.0 to 35.0, with a
mean ±SD of 6.1 ±2.7 per 106 cells.
Compared with the liquidator group, the
difference was also significant atp <0.01.
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Discussion
Various biological methods have been
developed to estimate human exposure to
ionizing radiation. These are based mainly
on chromosomal damage and mutagenic
changes at the cellular level (1). One sensi-
tive technique, originally described by
Langlois et al. (2,9), measures the fre-
quency ofred cells carrying a mutation at
the GPA locus in red cells, presumably
because of mutation oferythroid precur-
sor cells. In this technique, fluorescent
moncolonal antibodies specific for group
M or N alleles are used to identify the cell
that expresses only one allele. It was found
that the normal frequency ofvariant cells
missing the M or N allele is about 1 in
105. Langlois et al. (8) also described an
improved version of this method using a
single-beam cytometer (BR6), which led to
improved separation ofnormal and mutant
phenotypic cells.
The GPA gene is present in single copy
in the genome ofchromosome 4 (10,11).
The protein coding region of the GPA
gene is 453 nucleotides in length and con-
sists of 7 exons and 6 introns extending
over 40 kb. The GPA gene occurs as two
common alleles, GPAM and GPAN, that
are responsible for MN blood groups. GPA
can carry either blood group M or N anti-
gen, as determined by the amino acid
sequence at residue 1 and residue 5 ofthe
mature glycoprotein that is. Ser1/Gly5 for
M and Leul/Glu5 for N (12,13). These
antigens differ by only 2 amino acids out
of 131. The two alleles are co-dominantly
expressed as MN heterozygotes and
approximately equally represented in the
human population, so that heterozygotes
represent about 50% of all individuals.
Hence, only 50% ofthe population can be
analyzed because they are heterologous at
this locus (14).
Exposure to mutagens such as ionizing
radiation can cause damage to precursor
erythroid cells ofthe bone marrow. Grant
and Bigbee (15) reported that the GPA
assay distinguishes between two indepen-
dent classes ofvariant cells. In one class,
the expression of one allelic form of GPA
surface protein is lost, and in the second,
in addition to allelic loss the cells express
the remaining homolog at twice the level
of the heterozygote. Thus, in individuals
having MN blood type, the GPA mutants
are recognized on rare red blood cell vari-
ants as either the simple loss of M or N
expression (N0, M0), termed hemizy-
gous mutations, or loss of expression of
one of the alleles, with double expression
of the other (NN, MM, with the muta-
tion being called homozygous). The nat-
ural frequency ofvariants was estimated
to be 7.1 ±5.6 per 106 cells (16), but nat-
uraly increases with age (17) and with
smoking (18) have been observed.
The GPA assay was used to show
elevated levels of red cell variants due to
somatic mutation in human groups exposed
to radiation such as that from Hiroshima
and Nagasaki (2,3,19-22) and from the
Goiania radiation exposure accident (4).
Increases in the frequency ofvariants have
been found after exposure to mutagenic
drugs (23) as well as in cancer-susceptible
patients with ataxia telangiectasia (24) and
Bloom's syndrome (25,26). It has been
suggested, therefore, that the GPA somatic
mutation assay has value for the assessment
ofcancer risk (20,27).
Jensen et al. (5) evaluated clean-up
workers from Russia and Ukraine and
found in 1 15 individuals a significant
increase ofN0 red cells corresponding to
the estimated radiation exposure. The
increased frequency of N0 variants was
stable in 10 donors over a 7-year period.
Somatic mutation analyses using the
GPA assay were also carried out by
Bigbee et al. (6,7) on Estonian clean-up
workers exposed to ionizing radiations as
a result of the. Chernobyl accident.
However, in the latter group, the fre-
quency of variant erythrocytes was low,
suggesting that the dose to the workers
did not exceed 10 cGy, probably too low
a dose to result in detectable damage to
erythroid stem cells.
The natural frequency ofN0 red cells
was reported byJensen et al. to be 7.1 ± 5.6
per 106 cells in U.S. residents not exposed
to radiation (16) and 6.6±4.7 per 106
cells (5) for unexposed Ukrainian and
Russian subjects. These values compare
well with those for our Russian control
group (6.1 ±2.7 per 106 cells), whereas the
frequency we observed in Israeli residents
was somewhat lower at 3.0± 0.8 per 106
cells though the difference was not statisti-
callysignificant.
In this study we have used the GPA
assay to measure the frequency of muta-
tions in red cells of salvage workers (liq-
uidators) of the Chernobyl accident who
had immigrated to Israel. Our measure-
ments, which were carried out 9 to 10
years after the accident, showed signifi-
cant elevation in the number of variant
red cells of liquidators compared to the
number observed among Israeli and FSU
immigrant control subjects.
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Figure 1. Frequency of variant red cells having N0 or
NN pheonotypes.
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These results suggest the presence of
clones ofphenotypically variant red cells
in which the N antigen is missing or
duplicated, presumably an indication of
mutated red cell erythroid precursor cells
in the bone marrow.
Kyoizumi et al. (20) reported a slightly
greater frequency of GPA N0 cells in
males than in females (by -10%) in unex-
posed survivors in Hiroshima andNagasaki,
but no effect ofsex on dose response was
observed. Although control groups con-
tained a lower proportion ofmales, com-
pared to the liquidator group, the marked
difference reported between liquidators
and controls is not explainable on the basis
ofthe natural male-to-female difference in
N0 frequency.
The effects noted in this study may be
attributable to radiation exposure on the
part of the liquidators during the course
of their activities at the Chernobyl site
9 to 10 years earlier. Therefore, it was
important to compare these effects with
those of unexposed persons who had
emigrated from the FSU as well as with
those of residents of Israel. The fact that
the emigrant FSU control subjects did
not show the effect on N0 frequency
as seen in liquidators does not support
the possibility that mutagic agents
(apart from radiation) in their previous
residential or working environments
caused these changes.
A rough estimation ofradiation expo-
sure dose based on the results ofthe GPA
somatic mutation assay may be obtained by
the method of Straume et al. (28) who
used the following equation:
H= [(N0W -N0b)/slope ofstandard
curve] x Q,
where
H=dose equivalent in Sv,
N0W=frequency ofN0 variants in the
radiation exposed person,
N0b=frequency ofN0 variants in
unexposed controls
Q=quality factor
The slope N0 per Gy was estimated by
Straume et al. (28) on the basis ofresults
obtained from Hiroshima atomic bomb sur-
vivors and from Goiania radiation accident
victims. Values for Hiroshima survivors led
to slope values of48x 10-6 per Gy from
data ofLanglois et al. (3), and independent
GPA measurements by Kyoizumi et al. (19)
provided N0 values for Hiroshima sur-
vivors of40x 10-6 per Gy. These values
were ofcourse based on radiation exposures
that occurred about 40 years before the
GPAmeasurements were made.
More recent exposures from the 1987
Goiania radiation accident were tested by
Straume et al. (4). In this accident, Cs-137
exposure was received over a period ofabout
2 weeks. Using dose esimates ofRamalho et
al. (29), the slope was estimated to be
12.8 x 104 per Gy.
The Chernobyl liquidators were exposed
primarily to external 'shine' radiation and
inhalation ofemitted radionuclides, primar-
ily 3 and y, although some at emitters were
also present. Therefore, the qualityfactorcan
be assumed to be equal to one.
Control variant cell frequencies (from
unirradiated Israeli residents) averaged
3.9 ±0.8 per 106 cells, whereas 15 liquidators
showed values averaging 25.5 ±7.0 per 106
cells. Using the slope based on the Goiania
data, a rough estimate of 1.7 Sv mean expo-
sure dose is made. Using the slope from
Hiroshima, the estimate is 0.5 Sv. If the
value of 10 events per 106 cells is used for
background frequency ofvariant cells, then
the mimimal dose is 15.5/48=0.32 Sv.
Values in the range 0.3 to 1.7 Sv are consis-
tent with average doses of0.51 (acute) and
0.96 Gy (chronic) estimated by Lucas (30)
using fluorescence in situ hybridization for
12 exposed Chernobyl liquidators without
medical symptoms. Thus, these rough and
rather tentative estimates suggest that
radiation exposures occurred above 0.25 Sv,
which was the provisional upper limit
specified at the timeofthe accident.
Nevertheless, it must be pointed out the
nature ofthe exposures at Hiroshima dif-
fered considerably from those ofGoiania,
and both differed in terms of intensity,
duration, source ofradiation, and time of
GPA analysis from the exposure incurred by
the Chernobyl liquidators. Therefore, calcu-
lations ofdose to liquidators based on GPA
analyses of atom bomb survivors and
Goiainia findings are not necessarily reliable.
The difference between these results,
which support those ofJensen et al. (5),
and the low values found in the studies by
Bigbee et al. (6,7) with groups ofliquida-
tors from Baltic countries is ofinterest, and
may indicate that radiation exposures to
different liquidator groups were not uni-
form. Correlating the results ofbiological
indicators ofexposurewith dose reconstruc-
tion estimates probablywould be useful.
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